GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Guangzhou Baiyunshan Pharmaceutical Holdings
Who Owns Guangzhou Baiyunshan Pharmaceutical Holdings Company?
Understanding a company's ownership is key to grasping its strategy and market impact. A significant development for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was its 2012 absorption of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. by Guangzhou Pharmaceutical Co. Ltd., leading to the adoption of its current name. This merger combined entities with market capitalizations of $2.2 billion and $1.2 billion, respectively, consolidating a substantial part of the pharmaceutical sector.
Founded in 1997 and based in Guangzhou, China, the company operates across the entire pharmaceutical value chain. As of July 29, 2025, its market capitalization is $5.74 billion with 1.63 billion shares outstanding.
Tracing the ownership evolution, founder stakes, and key investors reveals the forces shaping this major pharmaceutical entity. For instance, its product portfolio includes offerings analyzed in the Guangzhou Baiyunshan Pharmaceutical Holdings BCG Matrix.
Who Founded Guangzhou Baiyunshan Pharmaceutical Holdings?
Information regarding the specific individual founders and their initial equity split for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, established on September 1, 1997, is not publicly detailed. However, its early ownership structure was significantly shaped by its parent entity, Guangzhou Pharmaceutical Holdings Limited (GPHL).
Company Inception
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was founded on September 1, 1997. Its early development was closely tied to the broader state-owned enterprise landscape.
State-Owned Influence
Both Guangzhou Pharmaceutical and its subsidiary, Guangzhou Baiyunshan Pharmaceutical, were identified as wholly state-owned companies. This indicates substantial state control from the outset.
Restructuring Impact
A significant restructuring in 2012 saw Guangzhou Pharmaceutical Co. Ltd. acquire the assets of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. The surviving entity became the current Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited.
Parent Company Role
The early ownership of Guangzhou Baiyunshan Pharmaceutical was heavily influenced by its parent, Guangzhou Pharmaceutical Holdings Limited. This relationship defined its initial corporate framework.
Lack of Individual Founder Data
Specific details about individual founders and their initial shareholdings are not readily available in public records. The focus remains on the corporate structure and state ownership.
Ownership History Context
Understanding Guangzhou Baiyunshan ownership requires acknowledging its evolution as a state-influenced entity. This history is crucial for grasping its current Baiyunshan Pharmaceutical ownership.
The Guangzhou Baiyunshan Pharmaceutical Holdings Company structure reflects a history of state consolidation. While specific individual founder stakes at inception are not detailed, the company's origins are rooted in state-owned enterprises, with Guangzhou Pharmaceutical Holdings Limited playing a pivotal role. This state backing has historically influenced its investment structure and corporate governance. The company's strategic direction, as seen in its Marketing Strategy of Guangzhou Baiyunshan Pharmaceutical Holdings, is often aligned with broader state economic objectives.
Key Ownership Aspects
The ownership of Guangzhou Baiyunshan Pharmaceutical Holdings Company is characterized by significant state influence, stemming from its parent company, Guangzhou Pharmaceutical Holdings Limited. This has shaped its corporate governance and market approach.
- Guangzhou Baiyunshan Pharmaceutical Holdings Company is a listed entity.
- Its origins are tied to wholly state-owned enterprises.
- Guangzhou Pharmaceutical Holdings Limited is the parent company.
- A 2012 restructuring consolidated assets under the current holding company.
How Has Guangzhou Baiyunshan Pharmaceutical Holdings’s Ownership Changed Over Time?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's ownership structure is primarily defined by its parent company's substantial stake, reflecting a strategic consolidation within the pharmaceutical sector. This structure influences its operational direction and market positioning.
| Shareholder Type | Percentage of Ownership (as of Jan 25, 2024) | Approximate Stake (as of Q3 2023) |
|---|---|---|
| Guangzhou Pharmaceutical Holdings Limited | 90.1% (as of March 31, 2025) | 1,464,610,206 shares |
| Private Companies | 46% | N/A |
| Individual Investors | 34% | N/A |
| Institutional Investors | 20% | 32.5% |
The ownership landscape of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is predominantly shaped by Guangzhou Pharmaceutical Holdings Limited, which maintains a controlling interest. This significant backing provides a stable foundation for the company's strategic initiatives and its Growth Strategy of Guangzhou Baiyunshan Pharmaceutical Holdings.
Key Institutional Investors
Beyond the majority shareholder, a diverse group of institutional investors plays a role in Baiyunshan Pharmaceutical's ownership. These entities often bring significant capital and strategic influence.
- Vanguard Group: Approximately 7.8% (as of Q3 2023)
- BlackRock: Approximately 5.2% (as of Q3 2023)
- China Life Insurance Company: Approximately 8.5% (as of Q3 2023)
- Qingdao Sea Fortune Investment: 5.2%
- BOC International Holdings: 2.8% (increased holdings by 1.4 million shares)
- Other notable investors include China Asset Management Co. Ltd., E Fund Management Co., Ltd., Huatai-PineBridge Fund Management Co., Ltd., Bosera Asset Management Co., Ltd., HuaAn Fund Management Company Ltd., Harvest Fund Management Co. Ltd., China Universal Asset Management Company Ltd., China Merchants Fund Management Company Ltd., State Street Global Advisors, Inc., and GF Fund Management Co., Ltd.
Who Sits on Guangzhou Baiyunshan Pharmaceutical Holdings’s Board?
The Board of Directors for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is structured to ensure robust corporate governance, comprising both executive and independent non-executive members. As of June 23, 2025, these directors actively participate in key committees, guiding the company’s strategic direction and oversight.
| Director Name | Position | Key Committee Involvement |
|---|---|---|
| Li Xiaojun | Chairman | Audit Committee, Strategic Development and Investment Committee, Nomination and Remuneration Committee, Budget Committee |
| Cheng Ning | Executive Vice Chairman | Strategic Development and Investment Committee, Budget Committee |
| Li Hong | General Manager & Executive Director | Audit Committee, Nomination and Remuneration Committee |
| Hongjin Cheng | Executive Director | Budget Committee |
| Heping Tang | Executive Director | Strategic Development and Investment Committee |
| Chen Yajin | Independent Non-Executive Director | Audit Committee (Chair), Nomination and Remuneration Committee |
| Huang Min | Independent Non-Executive Director | Strategic Development and Investment Committee, Budget Committee |
| Wong Lung Tak Patrick | Independent Non-Executive Director | Audit Committee, Strategic Development and Investment Committee |
| Sun Baoqing | Independent Non-Executive Director | Nomination and Remuneration Committee, Budget Committee |
The voting power within Guangzhou Baiyunshan Pharmaceutical Holdings Company is largely influenced by its share structure and major shareholders. The company operates on a one-share-one-vote principle, with a total of 1,625,790,949 shares issued as of December 31, 2024. This framework ensures that shareholders’ influence is directly proportional to their equity stake, a common practice in corporate governance.
Understanding Guangzhou Baiyunshan Pharmaceutical Holdings Company Structure
The ownership and governance structure of Guangzhou Baiyunshan Pharmaceutical Holdings Company is primarily shaped by its largest shareholder. This entity's significant stake directly impacts the company's strategic decisions and overall direction.
- Guangzhou Pharmaceutical Holdings Limited holds a substantial 90.1% ownership, indicating its controlling interest.
- The board comprises executive and independent non-executive directors, ensuring diverse perspectives.
- The average tenure of board members is 3.1 years, with an average age of 58.5 years.
- Understanding this structure is key to grasping the Baiyunshan Pharmaceutical ownership dynamics.
- For deeper insights into the company's guiding principles, explore the Mission, Vision & Core Values of Guangzhou Baiyunshan Pharmaceutical Holdings.
What Recent Changes Have Shaped Guangzhou Baiyunshan Pharmaceutical Holdings’s Ownership Landscape?
Recent developments at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited indicate a dynamic ownership landscape and strategic focus on growth. The company's commitment to shareholder returns is evident in its proposed 2024 dividend, while expansion into fund management signals a forward-looking investment strategy.
| Metric | Value | Date/Period |
| Proposed Cash Dividend per Share | RMB 0.40 | March 13, 2025 (for 2024) |
| Total Cash Dividend for 2024 | RMB 650,316,379.60 | Based on 2024 share capital |
| Total Shares in Issue | 1,625,790,949 | December 31, 2024 |
| Analyst Price Target (Hold) | HK$ 21.70 | June 2025 |
| Analyst Price Target (Sell) | HK$ 16.00 | August 2025 |
| Individual Investor Ownership | Approx. 34% | January 2024 |
| Private Company Ownership | 46% | January 2024 |
| Institutional Ownership (Jan 2024) | Approx. 20% | January 2024 |
| Institutional Ownership (Q3 2023) | 32.5% | Q3 2023 |
The ownership structure of Guangzhou Baiyunshan Pharmaceutical Holdings Company shows a significant concentration in private companies, which held 46% of the shares as of January 2024. Individual investors accounted for approximately 34% during the same period. Institutional ownership has seen an increase, rising from around 20% in January 2024 to 32.5% by the third quarter of 2023, with major players like Vanguard Group and BlackRock holding substantial stakes. This trend highlights a growing institutional interest in the company's performance and future prospects, contributing to the overall Baiyunshan Pharmaceutical ownership dynamics.
Shareholder Returns and Investment Focus
The company proposed a cash dividend of RMB 0.40 per share for 2024, demonstrating a commitment to rewarding shareholders. Furthermore, the establishment of the second phase of Guangyao Funds with Guangyao Capital signals an intensified focus on incubating and investing within the pharmaceutical and healthcare sectors.
Market Sentiment and Analyst Views
Recent analyst ratings present a mixed outlook. As of June 2025, one rating was 'Hold' with a price target of HK$ 21.70, while another rating in August 2025 was 'Sell' with a target of HK$ 16.00. These differing perspectives suggest varied interpretations of the company's valuation and future performance.
Ownership Breakdown and Trends
As of January 2024, private companies were the largest shareholders, holding 46% of Guangzhou Baiyunshan Pharmaceutical Holdings Company. Individual investors owned approximately 34%, while institutional investors held about 20%. This contrasts with Q3 2023 data, where institutional ownership stood at 32.5%, indicating a notable increase in institutional participation.
Key Institutional Investors
Significant institutional investors, including Vanguard Group and BlackRock, have established notable stakes in the company. Their involvement contributes to the growing institutional ownership trend and underscores the company's appeal within the broader investment community. Understanding the Revenue Streams & Business Model of Guangzhou Baiyunshan Pharmaceutical Holdings can provide further context to these investment patterns.
- What is Brief History of Guangzhou Baiyunshan Pharmaceutical Holdings Company?
- What is Competitive Landscape of Guangzhou Baiyunshan Pharmaceutical Holdings Company?
- What is Growth Strategy and Future Prospects of Guangzhou Baiyunshan Pharmaceutical Holdings Company?
- How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Work?
- What is Sales and Marketing Strategy of Guangzhou Baiyunshan Pharmaceutical Holdings Company?
- What are Mission Vision & Core Values of Guangzhou Baiyunshan Pharmaceutical Holdings Company?
- What is Customer Demographics and Target Market of Guangzhou Baiyunshan Pharmaceutical Holdings Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.